Halozyme Therapeutics
HALO
$38.46
Share price
-1.69%
Change (1 day)
14.57%
Change (1 year)
Categories
Halozyme Therapeutics (HALO) - Total debt
Total debt on the balance sheet as of December 2023 : $1.49 B
According to Halozyme Therapeutics's latest financial reports the company's total debt is $1.49 B. A company’s total debt is the sum of all current and non-current debts.
Halozyme Therapeutics - Total debt on balance sheet (from 2011 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $1.49 B | -0.45% |
| 2022-12-31 | $1.50 B | 71.8% |
| 2021-12-31 | $0.87 B | 120.7% |
| 2020-12-31 | $0.39 B | -1.33% |
| 2019-12-31 | $0.40 B | 218.55% |
| 2018-12-31 | $0.12 B | -37.54% |
| 2017-12-31 | $0.20 B | -6.59% |
| 2016-12-31 | $0.21 B | 334.69% |
| 2015-12-31 | $49.83 M | -0.05% |
| 2014-12-31 | $49.86 M | 0.18% |
| 2013-12-31 | $49.77 M | 59.98% |
| 2012-12-31 | $31.11 M | |
| 2011-12-31 | $N/A |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $29.33 B | 1,856.44% | 🇺🇸 USA |
 Pfizer PFE | $70.84 B | 4,625.36% | 🇺🇸 USA |
 Eli Lilly LLY | $25.22 B | 1,582.53% | 🇺🇸 USA |
 Sanofi SNY | $20.36 B | 1,258.49% | 🇫🇷 France |
 Baxter BAX | $14.36 B | 858.08% | 🇺🇸 USA |
 MannKind Corp MNKD | $0.27 B | -81.82% | 🇺🇸 USA |